vs

Side-by-side financial comparison of Everus Construction Group, Inc. (ECG) and Real Brokerage Inc (REAX). Click either name above to swap in a different company.

Everus Construction Group, Inc. is the larger business by last-quarter revenue ($1.0B vs $568.5M, roughly 1.8× Real Brokerage Inc). Everus Construction Group, Inc. runs the higher net margin — 5.5% vs -0.1%, a 5.5% gap on every dollar of revenue. On growth, Real Brokerage Inc posted the faster year-over-year revenue change (52.6% vs 33.2%). Everus Construction Group, Inc. produced more free cash flow last quarter ($23.5M vs $8.4M).

Anywhere Real Estate Inc., formerly Realogy, was an American real estate services firm. It operated and franchised real estate brands that provided brokerage, relocation, title, insurance, and settlement services. Brands included Better Homes and Gardens Real Estate, Century 21 Real Estate, Coldwell Banker, Corcoran Group, ERA Real Estate and Sotheby's International Realty. In 2026, the company was acquired by Compass, Inc.

ECG vs REAX — Head-to-Head

Bigger by revenue
ECG
ECG
1.8× larger
ECG
$1.0B
$568.5M
REAX
Growing faster (revenue YoY)
REAX
REAX
+19.5% gap
REAX
52.6%
33.2%
ECG
Higher net margin
ECG
ECG
5.5% more per $
ECG
5.5%
-0.1%
REAX
More free cash flow
ECG
ECG
$15.1M more FCF
ECG
$23.5M
$8.4M
REAX

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ECG
ECG
REAX
REAX
Revenue
$1.0B
$568.5M
Net Profit
$55.3M
$-447.0K
Gross Margin
11.6%
7.9%
Operating Margin
6.8%
-0.1%
Net Margin
5.5%
-0.1%
Revenue YoY
33.2%
52.6%
Net Profit YoY
60.4%
82.7%
EPS (diluted)
$1.09
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ECG
ECG
REAX
REAX
Q4 25
$1.0B
Q3 25
$986.8M
$568.5M
Q2 25
$921.5M
$540.7M
Q1 25
$826.6M
$354.0M
Q4 24
$759.6M
Q3 24
$761.0M
$372.5M
Q2 24
$703.4M
Q1 24
$625.7M
$200.7M
Net Profit
ECG
ECG
REAX
REAX
Q4 25
$55.3M
Q3 25
$57.0M
$-447.0K
Q2 25
$52.8M
$1.5M
Q1 25
$36.7M
$-5.0M
Q4 24
$34.5M
Q3 24
$41.8M
$-2.6M
Q2 24
$39.0M
Q1 24
$28.2M
$-16.1M
Gross Margin
ECG
ECG
REAX
REAX
Q4 25
11.6%
Q3 25
12.6%
7.9%
Q2 25
13.0%
8.9%
Q1 25
11.2%
9.6%
Q4 24
11.4%
Q3 24
11.8%
8.6%
Q2 24
12.6%
Q1 24
11.9%
10.3%
Operating Margin
ECG
ECG
REAX
REAX
Q4 25
6.8%
Q3 25
7.3%
-0.1%
Q2 25
7.9%
0.3%
Q1 25
6.2%
-1.5%
Q4 24
6.1%
Q3 24
7.1%
-0.7%
Q2 24
7.3%
Q1 24
6.2%
-7.8%
Net Margin
ECG
ECG
REAX
REAX
Q4 25
5.5%
Q3 25
5.8%
-0.1%
Q2 25
5.7%
0.3%
Q1 25
4.4%
-1.4%
Q4 24
4.5%
Q3 24
5.5%
-0.7%
Q2 24
5.5%
Q1 24
4.5%
-8.0%
EPS (diluted)
ECG
ECG
REAX
REAX
Q4 25
$1.09
Q3 25
$1.11
$0.00
Q2 25
$1.03
$0.01
Q1 25
$0.72
$-0.02
Q4 24
$0.68
Q3 24
$0.82
$-0.01
Q2 24
$0.76
Q1 24
$0.55
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ECG
ECG
REAX
REAX
Cash + ST InvestmentsLiquidity on hand
$38.7M
Total DebtLower is stronger
$281.5M
Stockholders' EquityBook value
$629.8M
$53.6M
Total Assets
$1.7B
$145.2M
Debt / EquityLower = less leverage
0.45×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ECG
ECG
REAX
REAX
Q4 25
Q3 25
$38.7M
Q2 25
$49.7M
Q1 25
$24.7M
Q4 24
Q3 24
$553.0K
$22.6M
Q2 24
Q1 24
$20.1M
Total Debt
ECG
ECG
REAX
REAX
Q4 25
$281.5M
Q3 25
$285.1M
Q2 25
$288.6M
Q1 25
$292.1M
Q4 24
$295.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ECG
ECG
REAX
REAX
Q4 25
$629.8M
Q3 25
$573.0M
$53.6M
Q2 25
$514.4M
$49.2M
Q1 25
$460.2M
$32.8M
Q4 24
$422.6M
Q3 24
$453.3M
$29.8M
Q2 24
$490.0M
Q1 24
$464.3M
$25.6M
Total Assets
ECG
ECG
REAX
REAX
Q4 25
$1.7B
Q3 25
$1.6B
$145.2M
Q2 25
$1.5B
$149.4M
Q1 25
$1.4B
$100.5M
Q4 24
$1.3B
Q3 24
$1.3B
$102.5M
Q2 24
Q1 24
Debt / Equity
ECG
ECG
REAX
REAX
Q4 25
0.45×
Q3 25
0.50×
Q2 25
0.56×
Q1 25
0.63×
Q4 24
0.70×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ECG
ECG
REAX
REAX
Operating Cash FlowLast quarter
$48.2M
$8.8M
Free Cash FlowOCF − Capex
$23.5M
$8.4M
FCF MarginFCF / Revenue
2.3%
1.5%
Capex IntensityCapex / Revenue
2.4%
0.1%
Cash ConversionOCF / Net Profit
0.87×
TTM Free Cash FlowTrailing 4 quarters
$90.0M
$71.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ECG
ECG
REAX
REAX
Q4 25
$48.2M
Q3 25
$76.2M
$8.8M
Q2 25
$25.3M
$41.0M
Q1 25
$7.1M
$15.9M
Q4 24
Q3 24
$78.9M
$7.2M
Q2 24
Q1 24
$21.9M
$21.5M
Free Cash Flow
ECG
ECG
REAX
REAX
Q4 25
$23.5M
Q3 25
$65.7M
$8.4M
Q2 25
$12.3M
$40.8M
Q1 25
$-11.4M
$15.7M
Q4 24
Q3 24
$60.9M
$6.8M
Q2 24
Q1 24
$12.6M
$21.4M
FCF Margin
ECG
ECG
REAX
REAX
Q4 25
2.3%
Q3 25
6.7%
1.5%
Q2 25
1.3%
7.5%
Q1 25
-1.4%
4.4%
Q4 24
Q3 24
8.0%
1.8%
Q2 24
Q1 24
2.0%
10.7%
Capex Intensity
ECG
ECG
REAX
REAX
Q4 25
2.4%
Q3 25
1.1%
0.1%
Q2 25
1.4%
0.0%
Q1 25
2.2%
0.1%
Q4 24
Q3 24
2.4%
0.1%
Q2 24
Q1 24
1.5%
0.0%
Cash Conversion
ECG
ECG
REAX
REAX
Q4 25
0.87×
Q3 25
1.34×
Q2 25
0.48×
27.13×
Q1 25
0.19×
Q4 24
Q3 24
1.89×
Q2 24
Q1 24
0.77×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ECG
ECG

Commercial$594.5M59%
Utility$203.5M20%
Industrial$82.8M8%
Institutional$66.1M7%
Service And Other$28.4M3%
Transportation$24.2M2%
Renewables$19.8M2%

REAX
REAX

Segment breakdown not available.

Related Comparisons